

IND

Austria at Bio Japan 2022



USTRY

Pacifico Yokohama

AT

12. – 14.10. 2022

ITS

www.advantageaustria.org/jp

BEST



FOR MORE INFORMATION

Advantage Austria Tokyo
3-13-3 Motoazabu, Minato-ku, Tokyo 106-0046
Japan
T +81 3 34 03 17 77
E tokyo@wko.at
W www.advantageaustria.org/jp

HALL | BOOTH

Pacifico Yokohama 1F Exhibition Hall – D65

EXHIBITING COMPANIES

ABA (Austrian Business Agency)
AOP Orphan Pharmaceuticals GmbH
APOSIENCE AG
Copa-Data GmbH
EUCODIS Bioscience GmbH
M bioserviceS GmbH
MChE Trading Handels-GmbH/F4-Pharma GesmbH
SCARLETRED Holding GmbH
Schalk Mühle GmbH & Co. KG

**Austrian Business Agency**

Opernring 3, 1010 Vienna

T +43 1588580

E office@aba.gv.atW <https://www.investinaustria.at>

ABA Japan representative:

Mr. Dominik-Christian Wraneschitz

T 03-3403-1777

E tokyo@advantageaustria.org

The Austrian Business Agency (ABA) is the location agency of the Republic of Austria. It provides companies interested in establishing themselves in Austria with free advice on all matters relating to the location, informs them about Austria as a business location and supports them in the formation of their company.

Services include:

- Business location data, facts, trends & developments
- Location search, selection and company formation
- Labour law and tax law information
- Funding and financing opportunities
- Formalities such as work permits and visas

Austria as a business location

The aim is to establish contacts with companies interested in Austria as a business location. The Austrian Business Agency (ABA) offers international investors tailor-made information (quickly, unbureaucratically, and free of charge).





AOP ORPHAN
FOCUS ON RARE DISEASES

AOP Orphan Pharmaceuticals GmbH

Leopold-Ungar-Platz 2, 1190 Vienna

T +43 150372440

E office@aoporphan.com

W <https://www.aoporphan.com>

The AOP Health Group comprises several companies, including AOP Orphan Pharmaceuticals GmbH, based in Vienna. AOP Health was founded in 1996 by Dr. Rudolf Widmann in Vienna specifically to provide individualised therapies for patients with rare diseases that had received little attention until then.

The company focuses on haematology and oncology, cardiology and pulmonology as well as neurology and metabolic diseases. Through the integration of Amomed Pharma GmbH and SciPharm s.r.l. in 2020, the company's portfolio was expanded to include intensive care and emergency medicine. AOP Health researches, develops, produces and distributes innovative preparations and applications worldwide in the respective focus areas.

Expansion of the international network

Success through cooperation and partnership

AOP Health attaches great importance to fair, balanced and sustainable, long-term partnerships as part of its international expansion. AOP Health is an experienced and reliable partner with a sales network in Europe that has grown over 26 years, international regional offices and sales cooperation agreements.

For the Asian market, AOP Health is striving for a diversified strategy in order to further expand and strengthen the existing network in cooperation with Asian partners.



Aposcience AG


Dresdner Straße 87/A 21, 1200 Vienna

E info@aposcience.com

W <https://www.aposcience.at>

Aposcience AG is a privately-owned company located in Vienna, Austria. Aposcience was a spin-off from the Medical University Vienna and develops first-in-class therapeutics targeting the cell regeneration process. Aposcience AG is a clinical-stage biopharmaceutical company with multiple development platforms for the treatment of patients with chronic inflammatory diseases.

The leading product of Aposcience is APOSEC, a topical agent for patients with diabetic foot ulcers, which is currently being evaluated in a Phase II study. This double blind, placebo-controlled clinical study is being carried out in four European countries and is expected to finish in mid-2023. The drug has been well tolerated so far with no drug-related adverse reactions. The estimated global market potential of APOSEC is up to > 10 million new DFU patients annually.



Facts about novel drug APOSEC

We are looking for the following business opportunities:

Partnership for Clinical Phase II

Partners for the implementation of Phase II/Phase III studies in Japan, Europe, China and the USA, preferably pharmaceutical companies with experience with blood and plasma products

The partner(s) will be given an option on the relevant patents that Aposcience has filed worldwide and the right to market the medicinal product in the territory to be agreed.

**Copa-Data GmbH**

Karolingerstraße 7b, 5020 Salzburg

T +43 6624310020

E sales@copadata.comW <https://www.copadata.com>

As an independent software manufacturer, COPA-DATA enables true industrial automation, digitization and progress in industries such as pharmaceuticals & life sciences, energy & infrastructure, automotive, manufacturing, process industry and food & beverage.


The zenon Software Platform from COPA-DATA is the leading industrial control system that is completely manufacturer-independent, works in any hardware and software environment and has more than 5,000 customers worldwide, including many Fortune Global 500 companies such as Pfizer, Volkswagen, AB InBev, Microsoft, BMW, Coca Cola, Nestlé, Mondelez or GE Energy.

**Industrial software for your digital transformation**

zenon software for the pharmaceutical industry

The zenon software platform from COPA-DATA has been specially developed for the challenges of companies in the pharmaceutical industry and helps to optimise all important processes with the help of innovative technologies.



**EUCODIS Bioscience GmbH**

Campus Vienna Biocenter II,
Viehmarktgasse 2a, 1030 Vienna
T +43 1 8900804-0

E office@eucodis.com

W <https://www.eucodis-enzymes.com/>

EUCODIS Bioscience develops and produces industrial special enzymes for the biopharmaceutical, fine chemical and cosmetics industries. EUCODIS markets over 50 enzymes, such as beta-lactamases for quality control in the production of antibiotics and lipases for the production of active pharmaceutical ingredients, as well as other enzymes such as peroxidases and phospholipases.



As a contract manufacturer, EUCODIS supplies its customers with individually customised, ISO9001-compliant services such as enzyme engineering, process development and production of sophisticated recombinant enzymes/proteins in the quantities desired.

We are looking for the following business opportunities:

Enzymes for api synthesis and other industrial applications

Enzyme solutions and services in the field of biocatalysis

Eucodis supplies beta lactamases (LacBuster), which are used for quality control in beta lactam production, and would like to acquire new customers with an interest in these products. Eucodis also seeks potential customers interested in new enzyme development projects or the production of individual enzymes.

**M bioserviceS GmbH**

Kapuzinerstrasse 82, 4020 Linz

T +43 699 11330130

E maria@mbioservices.comW <https://www.mbioservices.com>

M bioserviceS provides consultancy services for the biotechnology sector. The firm can count on its worldwide expertise and 20 years of industry experience.

Consulting activities:

- Procurement of critical biological raw materials
- Organization of transport and logistics
- Quality
- Regulatory Affairs
- Compliance
- Market development
- Import and export issues

Core competencies are concerned with raw materials and by-products of animal or human origin and the associated legal requirements worldwide. M bioserviceS GmbH supports the pharmaceutical industry, manufacturers of diagnostics, academic and industrial research, cell culture users and other biotechnology undertakings.

**DO YOU WORK WITH BIOLOGICAL MATERIALS?**

We can solve your problems!

M bioserviceS seeks partners and customers who produce or use biological raw materials.

M bioserviceS facilitates:

- Access to new sources of raw materials worldwide
- Procurement of rare biological raw materials
- Entry into new markets
- Customised transport and logistics concepts
- Regulatory support for import, export and registration matters
- Tailor-made solutions for product and business development





**MChE Trading Handels-GmbH/F4-Pharma
GesmbH**

Gersthofenstraße 103/23, 1180 Wien

T +43 664 1107694

E thomas.steiner@f4-pharma.com

W <http://www.f4-pharma.at/>

Founded in Vienna, Austria in May 2020, F4-Pharma is working on the registration of its molecule FX06 and its applications.

In the frame of the Horizon Europe project COVend, a Phase II clinical trial for treatment of mild to severe hospitalised COVID-19 patients with FX06 is being implemented in 8 European countries. The peptide FX06 has an effect in the treatment of the "capillary leak", an increased permeability of the capillary vessels which can have dramatic consequences in Intensive care. FX06 has also shown to have anti-inflammatory properties.

Further indications in intensive care medicine are under evaluation.

In Japan- F4-Pharma is co-operating with renowned universities.

FX06 Capillary leak / Anti inflammatory

F4-Pharma is interested in a co-operation with Japanese partners as follows:

- (1) a biotech or pharmaceutical company active or interested in intensive care applications
- (2) Scientific co-operations with Japanese research entities to develop further potential applications of FX06,
- (3) Potential investors in Biotech


**SCARLETRED GmbH**

Landstraße, Maria Jacobi Gasse 1, 1030 Wien

T +436644109404

E office@scarletred.comW <https://www.scarletred.com>

SCARLETRED is a leading digital health company based in Vienna and Boston. Based on AI, the patented and clinically validated medical device Scarletred®Vision enables standardized and location-independent documentation and analysis of skin changes in >3000 skin diseases. Used in daily clinical practice (geriatric care, chronic wounds), it saves time and helps in therapeutic decision-making. As a new gold standard, it provides valuable information on tested drugs and cosmetics safety and efficacy. The Software as a Subscription (SaaS) model is distributed to companies, hospitals, and insurance.

**Scarletred®Vision**

Global health with AI and a skin pad

Since 2015, the product has been distributed from Austria via B2B as SaaS to international biopharma and cosmetics companies. In addition to its use in industry, it is now increasingly being introduced in the clinical routine of academic institutions and hospitals, e.g. for chronic wounds progression.

SCARLETRED is looking for partners and investors who share the vision in life science and pharma.



Schalk Mühle GmbH & Co KG

Kalsdorf/18, 8262 Ilz

T: +43 3385312

E office@schalk-muehle.at

W <http://www.schalk-muehle.at>

Schalk Mühle produces regional and sustainable products to support a balanced and healthy diet.

Core capabilities:

For generations, the family firm has paid attention to supporting sustainable regional agricultural products and preserving traditional production processes. It cultivates close working relationships with regional organic farmers whose products, along with the firm's own, are processed to make high-quality foods at the Schalk Mühle.

IFS Food, Bio, Demeter, Bio Suisse, Naturland Fair, Vegan and many others certifications demonstrate that the products really are what they say they are.



Our services include:

HIGH-QUALITY FOODS FROM AUSTRIA
direct from the producer

Schalk Mühle stands for 100% transparency and produces products directly on site.
The range is very diverse, comprising products and services in the food sector:

- more than 70 different products
- own brand "Schalk Mühle"
- private label or white label
- bulk
- contract work (filling, packaging, pressing, grinding, processing etc.)



Notes

Advantage Austria Tokyo
3-13-3 Motoazabu, Minato-ku, Tokyo
106-0046 Japan
T +81 3 34 03 17 77
E tokyo@wko.at
W www.advantageaustria.org/jp

Access this booklet online:

English



Japanese

